2026年2月6日，证监会官网披露，华泰联合证券已提交《关于江苏烽禾升科技集团股份有限公司首次公开发行股票并上市辅导备案报告》。烽禾升的辅导 机构为华泰联合证券有限责任公司，律师事务所为安徽天禾律师事务所，会计师事务所为容诚会计师事务所（特殊普通合伙）。 关于江苏烽禾升科技集团股份有限公司首次 公开发行股票并上市辅导备案报告 江苏烽禾升科技集团股份有限公司，公司位于江苏省苏州市，是一家为新能源电池、汽车零部件、医疗器械等领域的全球头部企业提供一流的数字化、柔 性化智能制造生产解决方案及数据服务的高新技术企业。法定代表人杨平。 烽禾升的控股股东及持股比例情况如下：发行人控股股东为杨平，其直接持有烽禾升27．64％的股权。 天眼查信息显示，烽禾升历史上获得了中金资本、云岫资本、国富基金、跃为资本等投资机构的投资。 | | | | 【江苏烽禾升科技集团股份有限公司】的 3 条融资历程信息 | | | | --- | --- | --- | --- | --- | --- | | 序号 | 披露日期 | 融资轮次 | 融资金额 | 投资方 跃为资本 珠海金锚铭股权投资 基金合伙企业(有限 | 关联机构 | | | | ...

Core Viewpoint - The article highlights the efforts of COFCO Group to ensure a stable supply of food products during the Spring Festival by leveraging digital and intelligent technologies to meet consumer demand [1] Group 1: Production and Supply Chain Management - COFCO Oil's production bases have entered a high-efficiency operational state ahead of the festival, focusing on key popular products like flaxseed oil, peanut oil, and corn oil [1] - Since early December 2025, COFCO Oil has implemented capacity adjustments and flexible scheduling to ensure stable production lines, particularly at its smart production line in Chengdu, which can refine hundreds of tons daily and package tens of thousands of boxes [1] - COFCO Joycome has utilized a scientific staggered production approach across its nationwide factories to ensure seamless production transitions, allowing for continuous supply without interruptions [1] Group 2: Data-Driven Strategies - COFCO Joycome has introduced a "one area, one policy" strategy based on backend data analysis to accurately prepare inventory, catering to the diverse consumption needs of different regions [1]

"我们不仅深耕产品研发，更着力搭建高水平创新平台，为持续创新注入动力。"黑龙江中桂制药总经理 孙超展示着刚获批的"黑龙江省口服液体制剂开发及产业化中试熟化平台"认定文件。该平台是去年绥化 市仅有的两家省级认定平台之一，标志着企业从中试到规模化生产的全链条研发能力获得权威认可。持 续研发投入是平台高效运转的保障，企业每年投入约2000万元用于技术创新和新产品研制开发，以高投 入催生高质量成果。"盐酸氨溴索口服溶液的产业化"获黑龙江省科技成果转化二等奖，"左卡尼汀制剂 研发与产业化"入选省级重大科技成果产业化项目，获700万元资金支持，实现"研发—转化—产业化"良 性循环。 面对中药制造这一传统领域，创新同样不可或缺。在黑龙江瑞格制药有限公司的中药提取车间内，一场 以数字化、智能化为核心的技术改造正悄然推进。公司新增6台数字化提取罐和两台双效浓缩器，实现 煎煮过程的精准设定与全程监控。"过去我们靠老师傅看火候、凭经验，现在只需在触控屏上设定好参 数，设备就能稳定、连续自动化运行。"公司生产部部长董彦良介绍。设备的提档升级不仅大幅提升了 生产过程的稳定性和批次间的一致性，更能使中药有效成分的提取收率提高至少10%。 ...

Core Insights - Cloudflare (NET) is expected to report fourth-quarter 2025 results on February 10, 2026, with anticipated revenues between $588.5 million and $589.5 million, reflecting a year-over-year growth of 28.3% [1] - The company forecasts non-GAAP earnings of 27 cents per share for the fourth quarter, indicating a growth of 42.1% from the same quarter last year [2] Revenue Expectations - Cloudflare's revenue growth is likely driven by enterprises shifting from traditional cybersecurity solutions to a zero-trust approach, alongside an increase in high-value contracts [3] - The company has seen significant global expansion, generating approximately 50% of its 2024 revenues outside the United States, which has diversified its clientele and contributed to revenue growth [4] Customer Growth - As of the end of the third quarter 2025, Cloudflare had 295,552 paying customers, marking a 33.4% year-over-year increase [4] - The number of large customers contributing $100,000 in annual revenues rose to 4,009, a 23% increase year-over-year, with 297 new large customers added in the third quarter of 2026 [5] AI Contributions - Growth in Cloudflare's Workers AI inference and AI Gateway requests is expected to positively impact revenue, along with the rising adoption of its Model Context Protocol server [6] Challenges - The company faces challenges in closing large deals due to geopolitical and macroeconomic pressures, which may negatively affect revenue recognition and top-line growth [7] - Customer caution in IT spending and vendor onboarding, influenced by recent U.S. policy measures, is also impacting Cloudflare's performance [7] Earnings Prediction - Current analysis indicates that Cloudflare's earnings may not exceed expectations, as it holds a Zacks Rank 3 and an Earnings ESP of -1.62% [8]

Financial Data and Key Metrics Changes - Sales in Q4 were $1.1 billion, representing an increase of 5% in local currency or 8% on a reported basis [7][11] - Adjusted EPS for the quarter was $13.36, an 8% increase over the prior year, while reported EPS was $13.98 compared to $11.96 in the prior year [10][11] - Gross margin was 59.8%, a decrease of 140 basis points, impacted by unfavorable foreign currency and tariff costs [8][12] Business Line Data and Key Metrics Changes - Laboratory sales increased 3%, industrial sales increased 7%, and food retail sales grew 19% in the quarter [7][8] - Service revenue grew 8% in the quarter, including a 2% benefit from acquisitions [8] - For the full year, local currency sales increased 3%, with adjusted operating profit declining 1% and adjusted EPS increasing 4% [11][12] Market Data and Key Metrics Changes - Local currency sales in the Americas increased 7%, Europe increased 4%, and Asia increased 4% [7] - Local currency sales in China increased 3% during the quarter, with modest growth expected in 2026 [7][25] - Emerging markets outside of China accounted for 18% of sales in 2025 and grew above the company average [25] Company Strategy and Development Direction - The company is focused on driving growth through its Spinnaker sales and marketing program and innovative product portfolio [6] - Strategic initiatives include capitalizing on automation, digitalization, and onshoring investments globally [6][26] - The company aims to maintain its competitive advantage through continuous innovation and operational excellence [6][19] Management's Comments on Operating Environment and Future Outlook - Management noted that customers are expected to be cautious with investments at the start of the year due to geopolitical tensions and market uncertainties [14][31] - The company anticipates gradual improvements throughout the year, with a local currency sales growth forecast of approximately 4% for 2026 [15][16] - Management expressed confidence in their ability to execute growth initiatives and gain market share despite macroeconomic challenges [15][26] Other Important Information - Free cash flow for 2025 was $878 million, with a conversion ratio of 99% of adjusted net income [12] - The company expects total amortization for 2026 to be approximately $78 million and interest expense to be around $70 million [17][18] - Share repurchases are expected to be in the range of $825 million to $875 million [18] Q&A Session Summary Question: Customer caution in Q1 guidance - Management acknowledged that while there are positive headlines in pharma and life sciences, they expect customers to be cautious at the start of the year, which has been factored into their guidance [31][33] Question: Components of guidance regarding pricing and volume - Management indicated that pricing is expected to be around 3.5% for Q1, with a full-year expectation of 2.5% [34][36] Question: Food retail performance and outlook - Management noted that food retail is a lumpy business with project-based revenue, and while they are pleased with Q4 performance, they expect flat growth for the full year [55][56] Question: China market and pharmacopoeia opportunity - Management stated that while there is good engagement in China, the pharmacopoeia opportunity will support ongoing growth but is not expected to result in a significant step change [57][75] Question: Reshoring and onshoring opportunities - Management views reshoring as a longer-term opportunity, likely materializing in 2027 and beyond, as factories need to be built before orders can be realized [61][62] Question: European market performance - Management highlighted strong performance in Europe, particularly in product inspection, despite a softer economic backdrop [66][68] Question: Service business outlook - Management expects mid- to high-single-digit growth for the service business in 2026, with continued focus on penetrating the serviceable addressable market [71]

Financial Data and Key Metrics Changes - Sales in Q4 were $1.1 billion, representing an increase of 5% in local currency or 4% excluding acquisitions, and an 8% increase on a reported basis in US dollars [7] - Adjusted EPS for the quarter was $13.36, an 8% increase over the prior year, while reported EPS was $13.98 compared to $11.96 in the prior year [10][11] - Gross margin was 59.8%, a decrease of 140 basis points, impacted by unfavorable foreign currency and incremental gross tariff costs [8][9] - Adjusted operating profit amounted to $363 million, up 3% versus the prior year, with an adjusted operating margin of 32.1%, a decrease of 160 basis points [9][11] Business Line Data and Key Metrics Changes - Laboratory sales increased 3% in Q4, while industrial sales increased 7%, including a 3% benefit from acquisitions [7][8] - Food retail sales grew 19% in the quarter, and service revenue grew 8%, including a 2% benefit from acquisitions [8] - For the full year, local currency sales increased 3%, with adjusted operating profit declining 1% and adjusted EPS increasing 4% [11][12] Market Data and Key Metrics Changes - Local currency sales in the Americas increased 7%, Europe increased 4%, and Asia (rest of the world) also increased 4% [7] - Local currency sales in China increased 3% during the quarter, with modest growth expected in the lab and industrial segments [24][25] - Emerging markets outside of China accounted for 18% of sales in 2025 and grew above the company average due to dedicated resources and growth initiatives [25] Company Strategy and Development Direction - The company is focused on driving growth through the Spinnaker sales and marketing program and innovative product portfolio, capitalizing on automation, digitalization, and onshoring investments [6][19] - The company aims to maintain a strong culture of innovation and operational excellence to gain market share and deliver strong financial performance [6][26] - Future growth opportunities are anticipated from customer replacement cycles and investments in on- and nearshoring activities [26] Management's Comments on Operating Environment and Future Outlook - Management noted that while there have been favorable headlines in the pharma and life sciences markets, customers are expected to be cautious with investments at the start of the year [31][32] - The company does not anticipate significant improvement in market conditions in 2026 compared to the previous year, but remains confident in executing growth and productivity initiatives [14][15] - Management highlighted the importance of their innovative portfolio and strong global leadership positions in navigating ongoing market challenges [26] Other Important Information - Free cash flow for 2025 was $878 million, with a conversion ratio of 99% of adjusted net income [12] - Guidance for 2026 includes local currency sales growth forecast of approximately 4%, with adjusted EPS expected to be in the range of $46.05-$46.70, representing a growth rate of 8%-9% [15][18] Q&A Session Summary Question: Customer caution in pharma and life sciences - Management acknowledged that despite positive headlines, there is still uncertainty in the market leading to longer deal cycles and a cautious start to the year [31][32] Question: Components of guidance for pricing and volume - Management indicated that pricing is expected to start the year stronger due to mid-year pricing actions from the previous year, with a forecast of 3.5% for Q1 and 2.5% for the full year [34][35] Question: Growth in food retail - Management noted that food retail is a lumpy business with project-based revenue, and while they are pleased with Q4 performance, they expect flat growth for the full year 2026 due to tough comparisons [55][56] Question: Outlook for China and pharmacopoeia opportunity - Management stated that while there is good engagement in China, the pharmacopoeia opportunity will support ongoing growth but is not expected to result in a significant step change [57][75] Question: Reshoring and onshoring opportunities - Management views reshoring as a longer-term opportunity, likely materializing in 2027 and beyond, as factories need to be built before orders can be realized [61][62] Question: Performance in Europe - Management highlighted strong performance in Europe despite a softer economy, driven by effective sales strategies and innovation in product offerings [66][68] Question: Service business outlook - Management expects mid- to high-single-digit growth for the service business in 2026, with continued focus on penetrating the serviceable addressable market [70][71]

Financial Data and Key Metrics Changes - Sales in Q4 2025 were $1.1 billion, representing an 8% increase on a reported basis and a 5% increase in local currency, or 4% excluding acquisitions [6][10] - Adjusted EPS for the quarter was $13.36, an 8% increase over the prior year, while reported EPS was $13.98 compared to $11.96 in the prior year [9][10] - Gross margin was 59.8%, a decrease of 140 basis points, impacted by unfavorable foreign currency and tariff costs [7][11] Business Line Data and Key Metrics Changes - Laboratory sales increased 3%, industrial sales increased 7% (including a 3% benefit from acquisitions), and food retail sales grew 19% in the quarter [6][7] - Service revenue grew 8% in the quarter, including a 2% benefit from acquisitions [7] - For the full year 2025, local currency sales increased 3%, with adjusted operating profit declining 1% and adjusted EPS increasing 4% [10][11] Market Data and Key Metrics Changes - Local currency sales in the Americas increased 7%, Europe increased 4%, and Asia (rest of the world) increased 4% [6] - Local currency sales in China increased 3% during the quarter, with modest growth expected in 2026 [6][23] - Emerging markets outside of China accounted for 18% of sales in 2025 and grew above the company average [23] Company Strategy and Development Direction - The company is focused on driving growth through its Spinnaker sales and marketing program and innovative product portfolio, capitalizing on automation, digitalization, and onshoring investments [5][24] - The company aims to maintain a strong culture of innovation and operational excellence to gain market share and deliver strong financial performance [5][24] - Future growth opportunities are anticipated from customer replacement cycles and investments in on- and nearshoring activities [24] Management's Comments on Operating Environment and Future Outlook - Management noted that customers are expected to be cautious with investments at the start of the year due to ongoing geopolitical tensions and market uncertainties [12][28] - The company does not anticipate significant improvement in market conditions in 2026 compared to the previous year, but remains confident in its growth and productivity initiatives [12][13] - Management highlighted the importance of their innovative portfolio and strong global leadership positions in navigating market challenges [24] Other Important Information - Adjusted free cash flow for 2025 was $878 million, with a conversion ratio of 99% of adjusted net income [11] - Guidance for 2026 includes local currency sales growth of approximately 4%, adjusted EPS forecasted to be in the range of $46.05-$46.70, representing an 8%-9% growth rate [13][15] Q&A Session Summary Question: Customer caution in pharma and life sciences - Management acknowledged that while headlines have improved, there is still uncertainty leading to longer deal cycles, and customers are expected to start the year cautiously [28][30] Question: Components of guidance regarding pricing and volume - Management indicated that pricing is expected to start strong due to mid-year pricing actions from the previous year, with a forecast of 3.5% for Q1 and 2.5% for the full year [32][33] Question: Q1 guidance and market assumptions - Management provided insights into expected growth rates across different business lines, indicating a cautious outlook for Q1 compared to Q4 [40][41] Question: Food retail performance and outlook - Management noted that food retail is a lumpy business with project-based revenue, guiding for flat growth in 2026 after strong performance in 2025 [54][55] Question: China market and pharmacopoeia opportunity - Management expressed optimism about the ongoing growth in China, particularly in the pharmaceutical sector, but noted that significant changes are not expected immediately [56][74] Question: Reshoring and onshoring opportunities - Management sees reshoring as a longer-term opportunity, primarily beyond 2026, as factories need to be built before significant orders can be expected [60][62]

Core Viewpoint - The company is actively engaging in research and development of new technologies and applications, particularly in digitalization and AI, to enhance its products and technologies [1] Group 1 - The company is arranging for relevant technical R&D personnel to study and research new technologies and examples [1] - The company is collaborating with external research institutions and technology companies to promote the application of cutting-edge technologies [1] - The goal is to empower the company's products and technologies through these advancements [1]

Core Viewpoint - The company aims to enhance its production processes through automation and digitalization by 2026, focusing on the upgrade of insulation molding parts processing lines [2] Group 1: Company Strategy - The company plans to introduce industrial robots to achieve precision and efficiency in key operations [2] - The automation upgrade is expected to optimize labor costs and improve production efficiency and product quality stability [2] - These initiatives are intended to further strengthen the company's competitive advantage in the market [2]

【纠错】 【责任编辑:施歌】 新华社北京2月6日电（记者古一平）春节是一年之中民生消费比较集中的关键节点。记者2月6日从 中粮集团获悉，中粮集团旗下各生产基地通过加强数字化、智能化技术赋能，全力保障节日市场"不断 档、不缺货"，确保节日餐桌产品供应充足，让消费者吃得好、吃得健康。 中粮油脂的相关生产基地在节前已进入高效运转状态。据介绍，自2025年12月初，中粮油脂对旗 下"福临门"等品牌的重点畅销产品亚麻籽油、花生油、玉米油等进行产能倾斜与弹性排产，确保生产线 高效稳定运行。其中，中粮油脂位于成都的亚麻籽油智慧生产线具备日精炼数百吨、日灌装数万箱的能 力，实现"人休机不休"。 猪肉产品供应方面，中粮家佳康依托在全国布局的多家工厂，实施科学的梯次排产与产能联动，实 现"此休彼产，无缝衔接"。此外，中粮家佳康还通过后台数据分析，推出"一地一策"精准备货方案，努 力满足各地消费者不同的消费需求。 ...